RYTM Q2 EPS Forecast Boosted by Needham & Company LLC

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) - Investment analysts at Needham & Company LLC lifted their Q2 2025 earnings per share (EPS) estimates for shares of Rhythm Pharmaceuticals in a report released on Monday, April 14th. Needham & Company LLC analyst J. Stringer now forecasts that the company will earn ($0.47) per share for the quarter, up from their previous forecast of ($0.49). Needham & Company LLC has a "Buy" rating and a $66.00 price objective on the stock. The consensus estimate for Rhythm Pharmaceuticals' current full-year earnings is ($4.32) per share. Needham & Company LLC also issued estimates for Rhythm Pharmaceuticals' Q3 2025 earnings at ($0.59) EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($1.96) EPS, FY2026 earnings at ($0.94) EPS, FY2028 earnings at $4.25 EPS and FY2029 earnings at $6.53 EPS.

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.03). The company had revenue of $41.83 million for the quarter, compared to analyst estimates of $38.48 million. Rhythm Pharmaceuticals had a negative return on equity of 367.36% and a negative net margin of 230.07%.

A number of other equities research analysts have also weighed in on RYTM. Stifel Nicolaus initiated coverage on Rhythm Pharmaceuticals in a report on Wednesday, March 5th. They issued a "buy" rating and a $78.00 price objective on the stock. Wells Fargo & Company raised their target price on Rhythm Pharmaceuticals from $80.00 to $91.00 and gave the company an "overweight" rating in a report on Monday, April 7th. Morgan Stanley reiterated an "overweight" rating and issued a $72.00 price target on shares of Rhythm Pharmaceuticals in a report on Friday, March 7th. HC Wainwright restated a "buy" rating and set a $80.00 target price (up from $70.00) on shares of Rhythm Pharmaceuticals in a research report on Tuesday, April 8th. Finally, Canaccord Genuity Group lifted their price target on shares of Rhythm Pharmaceuticals from $81.00 to $92.00 and gave the company a "buy" rating in a research report on Tuesday, April 8th. Thirteen analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $74.92.

Rhythm Pharmaceuticals Price Performance

Shares of RYTM stock traded up $0.21 during mid-day trading on Thursday, hitting $60.69. The stock had a trading volume of 280,574 shares, compared to its average volume of 542,095. Rhythm Pharmaceuticals has a fifty-two week low of $35.17 and a fifty-two week high of $68.58. The company's 50-day simple moving average is $54.84 and its 200-day simple moving average is $55.81. The firm has a market cap of $3.84 billion, a PE ratio of -14.03 and a beta of 2.32.

Hedge Funds Weigh In On Rhythm Pharmaceuticals

Hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC raised its holdings in shares of Rhythm Pharmaceuticals by 0.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,256,188 shares of the company's stock worth $65,824,000 after purchasing an additional 3,499 shares during the period. Janus Henderson Group PLC lifted its position in Rhythm Pharmaceuticals by 103.9% during the fourth quarter. Janus Henderson Group PLC now owns 1,219,554 shares of the company's stock valued at $68,309,000 after buying an additional 621,432 shares in the last quarter. Marshall Wace LLP grew its stake in Rhythm Pharmaceuticals by 70.4% during the fourth quarter. Marshall Wace LLP now owns 692,803 shares of the company's stock worth $38,783,000 after buying an additional 286,188 shares during the period. Price T Rowe Associates Inc. MD increased its position in shares of Rhythm Pharmaceuticals by 24.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 685,152 shares of the company's stock worth $38,355,000 after acquiring an additional 134,622 shares in the last quarter. Finally, Hood River Capital Management LLC raised its stake in shares of Rhythm Pharmaceuticals by 4.7% in the 4th quarter. Hood River Capital Management LLC now owns 643,691 shares of the company's stock valued at $36,034,000 after acquiring an additional 29,093 shares during the period.

Insider Buying and Selling at Rhythm Pharmaceuticals

In related news, insider Joseph Shulman sold 1,281 shares of the company's stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $59.43, for a total value of $76,129.83. Following the completion of the transaction, the insider now directly owns 2,657 shares in the company, valued at approximately $157,905.51. This represents a 32.53 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CAO Christopher Paul German sold 635 shares of the firm's stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $57.22, for a total value of $36,334.70. Following the completion of the sale, the chief accounting officer now directly owns 2,070 shares in the company, valued at approximately $118,445.40. The trade was a 23.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 146,641 shares of company stock worth $8,112,177. Insiders own 5.60% of the company's stock.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.